ES2175439T3 - COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID. - Google Patents

COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID.

Info

Publication number
ES2175439T3
ES2175439T3 ES97933736T ES97933736T ES2175439T3 ES 2175439 T3 ES2175439 T3 ES 2175439T3 ES 97933736 T ES97933736 T ES 97933736T ES 97933736 T ES97933736 T ES 97933736T ES 2175439 T3 ES2175439 T3 ES 2175439T3
Authority
ES
Spain
Prior art keywords
nucleic acid
vesicles
compositions containing
tensioactives
invention refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97933736T
Other languages
Spanish (es)
Inventor
Patrick Mahy
Didier Roux
Rene Laversanne
Joelle Amedee
Olivier Freund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capsulis SA
Original Assignee
Capsulis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capsulis SA filed Critical Capsulis SA
Application granted granted Critical
Publication of ES2175439T3 publication Critical patent/ES2175439T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION QUE CONTIENE AL MENOS UN ACIDO NUCLEICO, UNA PARTE DEL CUAL SE ENCUENTRA INCLUIDA EN EL INTERIOR DE VESICULAS MULTILAMINARES, CARACTERIZADA PORQUE DICHAS VESICULAS ESTAN CONSTITUIDAS POR DOS CAPAS QUE COMPRENDEN AL MENOS UN AGENTE TENSIOACTIVO, SIENDO DICHAS CAPAS CONCENTRICAS Y PROPORCIONANDO A DICHAS VESICULAS UNA ESTRUCTURA EN FORMA DE CEBOLLA. LOS TENSIOACTIVOS UTILIZADOS SON TENSIOACTIVOS NO CATIONICOS. LA INVENCION SE REFIERE A LA UTILIZACION DE TALES COMPOSICIONES EN EL CAMPO FARMACEUTICO, EN PARTICULAR EN TERAPIA GENICA Y EN TRANSFECCION IN VITRO E IN VIVO.THE INVENTION REFERS TO A COMPOSITION THAT CONTAINS AT LEAST ONE NUCLEIC ACID, A PART OF WHICH IS INCLUDED IN THE INTERIOR OF MULTILAMINARY VESICLES, CHARACTERIZED BECAUSE SUCH VESICLES ARE CONSTITUTED BY TWO LAYERS THAT AGREE WITH LESS THAN ONE AND PROVIDING TO SUCH VESICLES A STRUCTURE IN THE FORM OF ONION. THE TENSIOACTIVES USED ARE NON-CATIONIC TENSIOACTIVES. THE INVENTION REFERS TO THE USE OF SUCH COMPOSITIONS IN THE PHARMACEUTICAL FIELD, IN PARTICULAR IN GENE THERAPY AND IN VITRO AND IN VIVO TRANSFECTION.

ES97933736T 1996-07-16 1997-07-15 COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID. Expired - Lifetime ES2175439T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608844A FR2751222B1 (en) 1996-07-16 1996-07-16 COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID AND THEIR APPLICATIONS IN THE BIOMEDICAL FIELD, PARTICULARLY IN GENE THERAPY

Publications (1)

Publication Number Publication Date
ES2175439T3 true ES2175439T3 (en) 2002-11-16

Family

ID=9494072

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97933736T Expired - Lifetime ES2175439T3 (en) 1996-07-16 1997-07-15 COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID.

Country Status (9)

Country Link
US (1) US6387396B2 (en)
EP (1) EP0935458B1 (en)
JP (1) JP2000516916A (en)
AU (1) AU722479B2 (en)
CA (1) CA2260284A1 (en)
DE (1) DE69711907T2 (en)
ES (1) ES2175439T3 (en)
FR (1) FR2751222B1 (en)
WO (1) WO1998002144A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2212305T3 (en) * 1997-06-23 2004-07-16 Alza Corporation POLINUCLEOTIDES ENCAPSULATED IN LIPOSOMES, COMPOSITION AND PROCEDURE.
FR2766706B1 (en) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa STABLE PARTICULATE COMPLEXES OF NEUTRAL OR NEGATIVE GLOBAL LOAD OF MULTILAMELLAR STRUCTURE COMPOSED OF AT LEAST ONE BIOLOGICALLY ACTIVE GLOBALLY ANIONIC SUBSTANCE AND A CATIONIC COMPONENT, THEIR PREPARATION AND USE
FR2766705B1 (en) * 1997-07-30 2001-05-25 Biovector Therapeutics PARTICLE COMPLEX OF NEUTRAL OR NEGATIVE GLOBAL CHARGE FORMED OF A CATIONIC OR NEUTRAL VESICLE AND A BIOLOGICALLY ACTIVE ANIONIC SUBSTANCE, THEIR PREPARATION AND THEIR USE
FR2769022B1 (en) * 1997-09-29 2000-11-03 Capsulis ANTIGEN VECTORS AND THERAPEUTIC COMPOSITIONS CONTAINING ANTIGENS
FR2790975B1 (en) * 1999-03-16 2001-06-01 Capsulis MEDIA IN THE FORM OF COMPLEX DISPERSIONS, THEIR PREPARATION PROCESS AND THEIR USES
FR2802422B1 (en) * 1999-12-21 2002-08-09 Capsulis MIXED STRUCTURES RESULTING FROM THE INCORPORATION OF A BIOLOGICAL MACROMOLECULE, PARTICULARLY DNA, IN A STRUCTURED PHASE OF AMPHIPHILES AND VESICLES OBTAINED FROM THESE STRUCTURES
WO2001064164A2 (en) * 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method
AU2002220522A1 (en) * 2000-12-01 2002-06-11 Novozymes A/S Encapsulation of compounds in vesicles
CA2553714A1 (en) * 2004-01-23 2005-08-04 Keio University Support accumulating in injured part in vascular channel
WO2006101201A1 (en) * 2005-03-24 2006-09-28 National University Corporation Hokkaido University Liposome capable of effective delivery of given substance into nucleus
GB0605521D0 (en) * 2006-03-18 2006-04-26 Isis Innovation Adjuvant
KR101601035B1 (en) 2013-02-28 2016-03-08 주식회사 종근당 Composition for gene delivery comprising chitosan and liquid crystal formation material

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5169637A (en) * 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5041278A (en) * 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE4005152A1 (en) * 1990-02-17 1991-08-22 Guenter Prof Dr Kahl Transforming plant protoplast(s) with DNA-histone complex - providing high and reproducible transfer rate, and expression of foreign genes
JPH07502510A (en) * 1991-12-17 1995-03-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Gene therapy for cystic fibrosis transmembrane conductance regulatory activity (CFTR)
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH09510433A (en) * 1993-12-17 1997-10-21 マイクロパック インコーポレイテッド Methods for delivering biologically active substances to cells
FR2714621B1 (en) * 1994-01-06 1996-02-23 Centre Nat Rech Scient Process for the preparation of liposomes without using an organic solvent.
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
US5627159A (en) * 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
AU6691496A (en) 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition

Also Published As

Publication number Publication date
EP0935458B1 (en) 2002-04-10
WO1998002144A1 (en) 1998-01-22
JP2000516916A (en) 2000-12-19
US20020012696A1 (en) 2002-01-31
AU3698297A (en) 1998-02-09
FR2751222B1 (en) 1998-10-09
DE69711907T2 (en) 2002-10-31
DE69711907D1 (en) 2002-05-16
FR2751222A1 (en) 1998-01-23
EP0935458A1 (en) 1999-08-18
AU722479B2 (en) 2000-08-03
CA2260284A1 (en) 1998-01-22
US6387396B2 (en) 2002-05-14

Similar Documents

Publication Publication Date Title
ES2175439T3 (en) COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID.
AU7040501A (en) Polymeric micelle compositions
SV1999000016A (en) DERIVATIVES OF 2- (PURIN-9-IL-TETRAHIDROFURAN-3,4-DIOL REF. PG3443 / SV
AR023574A1 (en) TETRACICLIC AZEPININDOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS TO PREPARE A MEDICINAL PRODUCT, AND INTERMEDIARIES
NO962088D0 (en) Preparation for in vivo production of therapeutic products
ES2187791T3 (en) COMPOSITIONS THAT UNDERSTAND CATIONIC AND CO-LIPID AMPHIFILES AND THAT FACILITATE THE ADMINISTRATION BY INTRACELLULAR VIA THERAPEUTIC MOLECULES.
ES2161085T3 (en) FORMULATIONS CONTAINING OXALIPLATIN.
CY1107054T1 (en) KINAZOLIN SOLUTION BITS
ATE337019T1 (en) CHARGED LIPIDS AND THEIR USE
BRPI9917007B8 (en) azabicycloalkanes as ccr5 modulators, pharmaceutical composition containing them, as well as their use
WO2002080965A3 (en) Vaccine composition
ES2165505T3 (en) AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
EA200300473A1 (en) THERAPEUTIC COMPOSITION ON THE BASIS OF MITOXANTRON (OPTIONS) AND LIPID PREPARATION, THE METHOD OF ITS OBTAINING AND THE METHOD OF TREATING THE MAMMALISM DISEASE WITH ITS USE
CR6656A (en) DOSAGE FORM OF DRUGS DRIVEN BY A HYDROGEL
ECSP083351A (en) PHARMACEUTICAL COMPOSITIONS
AR003427A1 (en) PEPTIDES RELATED TO DOLASTATIN, PROCEDURE FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE SAME FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITIONS.
AR008680A1 (en) SUBSTITUTES FOR PLATELETS AND CONJUGATION METHODS SUITABLE FOR THEIR PREPARATION
DK1272160T3 (en) Lipid-based drug delivery system for topical application
AR022358A1 (en) AN EPO COMPOSITION, A PROCEDURE FOR OBTAINING IT, A PHARMACEUTICAL PREPARATION CONTAINING IT AND A PROCEDURE TO INCREASE THE SPECIFIC ACTIVITIES OF AN EPO COMPOSITION
CO5160321A1 (en) NEW COMPOSITIONS OF TIPRANAVIR AND RITONAVIR
AR003589A1 (en) USE OF AN EFFECTIVE AMOUNT OF AT LEAST ONE PEPTIDE IN A COSMETIC COMPOSITION OR FOR THE PREPARATION OF A MEDICATION INTENDED TO PARATRATE INFLAMMATION, AND A COSMETIC TREATMENT PROCEDURE THROUGH A COSMETIC COMPOSITION CONTAINING SUCH PEPTIDE.
UY28536A1 (en) DERIVATIVES OF BENCIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION AND USES OF THE SAME.
ECSP045110A (en) COMPOSITIONS OF THE PREPARATION CONTAINING A PHYSIOLOGICALLY ACTIVE COMPOSITE OF UNSTABLE ACIDS AND PROCESSES FOR THEIR PRODUCTION
ES2161750T3 (en) USE OF 17ALFA-DIHYDROEQUYLENINE TO DECREASE THE LEVEL OF CHOLESTEROL.
ES2191643T3 (en) CHALCONA-CUMARINAS.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 935458

Country of ref document: ES